Syncom Formulations (India) Limited
NSE: SYNCOMF BSE: SYNCOMF
NSE
20.80
-0.40 (-1.89%)
Prev Close
21.2
Open Price
21.12
Volume
2,943,831
Today Low / High
20.68 / 21.25
52 WK Low / High
11.99 / 27.9
Range
20 - 22
BSE
20.85
-0.33 (-1.56%)
Prev Close
21.18
Open Price
21.16
Volume
186,541
Today Low / High
20.68 / 21.21
52 WK Low / High
12 / 27.94
Range
20 - 22
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 20.8 (target range: 20 - 22), reflecting a change of -0.4 (-1.88679%). On the BSE, it is listed at 20.85 (target range: 20 - 22), showing a change of -0.33 (-1.55807%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
06 Jun
21.12
-1.80%
05 Jun
20.91
1.39%
04 Jun
21.30
-2.21%
03 Jun
22.31
-5.02%
02 Jun
22.08
-1.18%
30 May
21.64
2.03%
29 May
22.26
-2.79%
28 May
22.30
-0.67%
27 May
19.93
10.74%
26 May
19.59
1.74%
23 May
19.80
-1.41%
22 May
20.01
-1.50%
21 May
19.86
0.76%
20 May
20.41
-3.23%
19 May
18.00
5.17%
16 May
17.03
2.70%
15 May
16.99
-0.35%
14 May
16.60
1.39%
13 May
16.45
0.30%
12 May
15.90
3.40%
Syncom Formulations (India) Limited Graph
Syncom Formulations (India) Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Syncom Formulations (India) Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 20.80, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 20.85 | 21.06 | 18.95 - 23.16 |
| 21.27 | 17.01 - 25.52 | ||
| 21.48 | 15.03 - 27.92 | ||
| Bearish Scenario | 20.85 | 20.64 | 18.58 - 22.71 |
| 20.43 | 16.35 - 24.52 | ||
| 20.22 | 14.16 - 26.29 |
Overview of Syncom Formulations (India) Limited
ISIN
INE312C01025
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
3,669,508
Market Cap
19,552,000,000
Last Dividend
0
Official Website
IPO Date
2022-11-18
DCF Diff
21.86
DCF
-1
Financial Ratios Every Investor Needs
Stock Dividend of SYNCOMF
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2022-09-09 | September 09, 22 | 0.03 | 0.03 | 2022-09-12 | 2022-10-19 | |
| 2017-09-21 | September 21, 17 | 0.02 | 0.02 | 2017-09-22 | 2017-10-29 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 259.24 Cr | 203.29 Cr | 55.95 Cr | 0.2158 | 0.00 Cr | 2.20 Cr | 24.93 Cr | 25.31 Cr | 0.27 | 43.03 Cr | 0.0976 |
| 2023-03-31 | 224.25 Cr | 141.70 Cr | 82.56 Cr | 0.3681 | 0.00 Cr | 2.62 Cr | 15.22 Cr | 20.07 Cr | 0.22 | 34.15 Cr | 0.0895 |
| 2022-03-31 | 217.82 Cr | 146.85 Cr | 70.97 Cr | 0.3258 | 0.00 Cr | 1.89 Cr | 15.99 Cr | 19.79 Cr | 0.24 | 31.96 Cr | 0.0909 |
| 2021-03-31 | 239.32 Cr | 167.07 Cr | 72.24 Cr | 0.3019 | 0.00 Cr | 1.42 Cr | 33.80 Cr | 29.17 Cr | 0.37 | 45.03 Cr | 0.1219 |
| 2020-03-31 | 200.08 Cr | 157.25 Cr | 42.83 Cr | 0.2140 | 0.00 Cr | 1.30 Cr | 12.67 Cr | 14.25 Cr | 0.18 | 21.88 Cr | 0.0712 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 63.29 Cr | 404.66 Cr | 117.35 Cr | 288.1428 Cr | 72.49 Cr | 9.19 Cr | 21.08 Cr | 72.31 Cr | 3.55 Cr | 0.12 Cr | 52.26 Cr | 106.5246 Cr |
| 2023-03-31 | 0.88 Cr | 377.83 Cr | 121.82 Cr | 256.0147 Cr | 83.18 Cr | 82.30 Cr | 21.20 Cr | 68.81 Cr | 4.64 Cr | 0.13 Cr | 73.20 Cr | 113.1596 Cr |
| 2022-03-31 | 0.22 Cr | 308.24 Cr | 86.02 Cr | 222.2216 Cr | 57.79 Cr | 57.57 Cr | 19.51 Cr | 52.71 Cr | 6.58 Cr | 0.11 Cr | 65.97 Cr | 78.2557 Cr |
| 2021-03-31 | 2.64 Cr | 291.65 Cr | 104.07 Cr | 187.5840 Cr | 62.09 Cr | 59.45 Cr | 22.56 Cr | 44.58 Cr | 5.30 Cr | 0.18 Cr | 8.82 Cr | 96.7040 Cr |
| 2020-03-31 | 8.09 Cr | 180.52 Cr | 34.87 Cr | 145.6502 Cr | 2.15 Cr | -5.94 Cr | 16.07 Cr | 45.88 Cr | 5.24 Cr | 0.25 Cr | 0.63 Cr | 27.7604 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | -5.9583 Cr | 83.0196 Cr | -14.5576 Cr | -14.0947 Cr | 62.5037 Cr | 63.3834 Cr | -8.1364 Cr | 25.3142 Cr | -10.6949 Cr | 0.0000 Cr | 0.1188 Cr |
| 2023-03-31 | 10.5293 Cr | -44.9527 Cr | 35.0014 Cr | -10.1054 Cr | 0.5780 Cr | 0.8797 Cr | -20.6347 Cr | 26.5593 Cr | 25.3907 Cr | -2.8200 Cr | -1.6940 Cr |
| 2022-03-31 | 16.3290 Cr | -27.0733 Cr | 8.2945 Cr | 5.0161 Cr | -2.4497 Cr | 0.3017 Cr | -11.3129 Cr | 26.1519 Cr | -4.2993 Cr | 0.0000 Cr | 3.0489 Cr |
| 2021-03-31 | -1.9935 Cr | -75.4625 Cr | 71.9604 Cr | -4.7189 Cr | -2.7307 Cr | 5.4768 Cr | -2.7254 Cr | 40.6739 Cr | 59.9425 Cr | 0.0000 Cr | -6.4829 Cr |
| 2020-03-31 | -0.5057 Cr | 1.3528 Cr | 0.0113 Cr | -2.2537 Cr | 0.8585 Cr | 8.2075 Cr | -1.7481 Cr | 17.3407 Cr | -6.5269 Cr | 0.0000 Cr | -2.3487 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 127.53 Cr | 86.66 Cr | 40.88 Cr | 0.3205 | 13.42 Cr | 13.00 Cr | 0.14 | 18.77 Cr | 0.1019 |
| 2024-09-30 | 102.31 Cr | 65.80 Cr | 36.51 Cr | 0.3569 | 10.86 Cr | 11.11 Cr | 0.16 | 16.31 Cr | 0.1086 |
| 2024-06-30 | 87.26 Cr | 65.46 Cr | 21.79 Cr | 0.2498 | 9.15 Cr | 7.63 Cr | 0.11 | 11.79 Cr | 0.0875 |
| 2024-03-31 | 74.57 Cr | 52.69 Cr | 21.89 Cr | 0.2935 | 8.13 Cr | 7.40 Cr | 0.10 | 12.52 Cr | 0.0993 |
| 2023-12-31 | 65.14 Cr | 50.71 Cr | 14.43 Cr | 0.2215 | 5.91 Cr | 7.00 Cr | 0.07 | 11.89 Cr | 0.1075 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 0.25 Cr | 91.76 Cr | 92.01 Cr | 0.00 Cr | 45.05 Cr | 245.82 Cr | 71.41 Cr | 372.45 Cr | 58.89 Cr |
| 2024-03-31 | 63.29 Cr | 63.70 Cr | 131.56 Cr | 114.01 Cr | 21.08 Cr | 274.78 Cr | 72.31 Cr | 404.66 Cr | 116.52 Cr |
| 2023-12-31 | -61.39 Cr | 122.78 Cr | 61.39 Cr | 0.00 Cr | 0.00 Cr | 61.39 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 0.17 Cr | 61.22 Cr | 61.39 Cr | 93.91 Cr | 20.15 Cr | 190.92 Cr | 72.67 Cr | 403.69 Cr | 133.52 Cr |
| 2023-06-30 | -70.90 Cr | 141.79 Cr | 70.90 Cr | 0.00 Cr | 0.00 Cr | 70.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 7.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 7.00 Cr | 2.89 Cr | 0.00 Cr | 0.00 Cr | 2.89 Cr | 3.06 Cr | 0.17 Cr | 0.00 Cr | 2.89 Cr |
| 2023-09-30 | 6.51 Cr | 1.76 Cr | 0.00 Cr | 0.00 Cr | 1.76 Cr | 0.17 Cr | -1.59 Cr | 0.00 Cr | 1.76 Cr |
| 2023-06-30 | 4.40 Cr | 2.20 Cr | 0.00 Cr | 0.00 Cr | 2.20 Cr | 3.08 Cr | 0.88 Cr | 0.00 Cr | 2.20 Cr |
| 2023-03-31 | 8.47 Cr | 2.34 Cr | 0.00 Cr | 0.00 Cr | 2.34 Cr | 0.88 Cr | -1.46 Cr | 0.00 Cr | 2.34 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,680.90 | ₹4,032,949,752,000.00 | ₹2,500,047.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,557.50 | ₹1,740,812,967,500.00 | ₹361,092.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,319.70 | ₹1,099,459,252,494.00 | ₹2,158,757.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,159.00 | ₹1,069,147,755,000.00 | ₹86,576.00 |
| Mankind Pharma Limited | MANKIND | ₹2,355.00 | ₹971,840,322,750.00 | ₹353,199.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹959.10 | ₹965,075,193,000.00 | ₹810,158.00 |
| Lupin Limited | LUPIN | ₹1,995.10 | ₹911,152,194,500.00 | ₹1,289,550.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,161.90 | ₹674,833,843,800.00 | ₹392,642.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,868.50 | ₹582,102,202,500.00 | ₹181,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,589.00 | ₹448,417,389,000.00 | ₹940,297.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,053.00 | ₹402,843,059,424.00 | ₹209,682.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,370.00 | ₹347,574,480,000.00 | ₹594,779.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.00 | ₹345,121,920,000.00 | ₹1,658,783.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,572.00 | ₹321,273,664,000.00 | ₹84,218.00 |
| Piramal Enterprises Limited | PEL | ₹1,170.00 | ₹265,213,260,000.00 | ₹1,087,533.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,700.00 | ₹264,963,700,000.00 | ₹62,794.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,507.00 | ₹244,855,853,000.00 | ₹804,048.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,775.00 | ₹244,375,000,000.00 | ₹123,203.00 |
| Eris Lifesciences Limited | ERIS | ₹1,628.50 | ₹221,777,272,500.00 | ₹55,564.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹988.00 | ₹194,204,244,000.00 | ₹40,498.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,133.00 | ₹180,465,373,000.00 | ₹116,793.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,900.00 | ₹165,505,710,000.00 | ₹539,420.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,097.00 | ₹159,396,534,900.00 | ₹64,316.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹859.00 | ₹153,855,490,000.00 | ₹354,605.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹531.00 | ₹128,790,864,000.00 | ₹485,813.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,550.00 | ₹92,126,670,000.00 | ₹8,096.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹914.00 | ₹89,380,882,600.00 | ₹310,713.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹910.85 | ₹82,554,543,627.00 | ₹242,268.00 |
| Strides Pharma Science Limited | STAR | ₹787.25 | ₹72,555,085,575.00 | ₹430,449.00 |
| FDC Limited | FDC | ₹427.80 | ₹69,650,118,000.00 | ₹308,294.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.05 | ₹53,562,356,100.00 | ₹2,350,692.00 |
| Innova Captab Limited | INNOVACAP | ₹884.20 | ₹50,598,283,106.00 | ₹72,505.00 |
| Suven Life Sciences Limited | SUVEN | ₹220.91 | ₹48,174,727,340.00 | ₹1,476,187.00 |
| Sequent Scientific Limited | SEQUENT | ₹188.05 | ₹47,069,291,100.00 | ₹443,068.00 |
| Hikal Limited | HIKAL | ₹372.50 | ₹45,929,622,500.00 | ₹155,345.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹461.10 | ₹42,084,597,000.00 | ₹112,258.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹591.80 | ₹41,666,152,440.00 | ₹18,979.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹369.00 | ₹37,002,582,000.00 | ₹50,925.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹720.00 | ₹36,517,752,000.00 | ₹149,831.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,136.00 | ₹35,327,304,000.00 | ₹12,390.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.44 | ₹35,310,155,760.00 | ₹2,842,096.00 |
| Alembic Limited | ALEMBICLTD | ₹111.70 | ₹28,682,549,288.00 | ₹595,649.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹89.03 | ₹26,132,708,810.00 | ₹1,118,863.00 |
| Indoco Remedies Limited | INDOCO | ₹274.65 | ₹25,335,885,735.00 | ₹25,403.00 |
Key Executives
Chief Marketing Officer
Mr. Rakesh Ch. Srivastava
Gender: male
Year Born: 1962
President of Domestic Marketing
Mr. Rahul Vijay Bankda
Gender: male
Year Born: 1980
Chief Financial Officer & Compliance Officer
Mr. Ankit Kedarmal Bankda
Gender: male
Year Born: 1987
Vice President of Human Resources
Ms. Payal Ankur Bankda
Gender: female
Year Born: 1987
Whole Time Director
Ms. Rinki Ankit Bankda
Gender: female
Year Born: 1987
Executive Chairman & Whole- Time Director
Mr. Kedarmal Shankarlal Bankda M.Com
Gender: male
Year Born: 1952
MD and Executive & Non Independent Director
Mr. Vijay Shankarlal Bankda B. Com LLB
Gender: male
Year Born: 1958
Company Secretary & Compliance Officer
Ms. Vaishali Agrawal
Gender: female
Year Born:
President of Export Marketing
Mr. Ankur Vijay Bankda
Gender: male
Year Born: 1985
FAQs about Syncom Formulations (India) Limited
Who is the CEO of the company?
The CEO is Mr. Kedarmal Shankarlal Bankda M.Com.
What is the current market price of the stock?
The current price is ₹20.80.
What is the 52-week price range?
The range is ₹11.99-27.9.
What is the market capitalization of the company?
The market capitalization is ₹1,955.20 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 49.35.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Syncom Formulations (India) Limited (ISIN: INE312C01025) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹1,955.20 crores and an average daily volume of 3,669,508 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.